| ［1］ |
Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines⁃⁃Part II. National Alopecia Areata Foundation［J］. J Am Acad Dermatol, 2004,51（3）:440⁃447. doi: 10.1016/j.jaad.2003.09.032.
|
| ［2］ |
Ito T, Hashizume H, Shimauchi T, et al. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase［J］. J Dermatol Sci, 2013,69（2）:140⁃147. doi: 10.1016/j.jdermsci.2012.12.003.
|
| ［3］ |
Emer J. Platelet⁃rich plasma （PRP）: current applications in dermatology［J］. Skin Therapy Lett, 2019,24（5）:1⁃6.
|
| ［4］ |
Strazzulla LC, Wang E, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies［J］. J Am Acad Dermatol, 2018,78（1）:15⁃24. doi: 10.1016/j.jaad.2017.04.1142.
|
| ［5］ |
Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients［J］. J Am Acad Dermatol, 2017,76（1）:22⁃28. doi: 10.1016/j.jaad. 2016.09.007.
|
| ［6］ |
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2019,33（5）:850⁃856. doi: 10.1111/jdv.15489.
|
